Sleep Review
  • Disorders
    • Breathing Disorders
    • Insomnia
    • Hypersomnias
    • Movement Disorders
    • Circadian Rhythm Disorders
    • Parasomnias
  • Diagnostics
    • Screeners
    • In-Lab Tests
    • Home Based/Out of Lab
    • Connected Care
    • Consumer Sleep Tracking
  • Treatments
    • Therapy Devices
    • Pharmaceuticals
    • Surgeries & Procedures
    • Behavioral Sleep Medicine
  • Health
    • Parameters
    • Demographics
    • Sleep & Body Systems
    • Prevailing Attitudes
  • Practice Management
    • Money
    • Laws & Regulations
    • Marketing
    • Human Resources
  • Earn CEC
  • Resources
    • Podcasts
    • Webinars
    • White Papers
    • Videos
  • Digital Edition

Select Page

Category: Non-24-Hour Disorder

Non-24-Hour Disorder

Latest
Some States Extend HETLIOZ Coverage to Patients With Non-24 Who Are Not Totally Blind

Some States Extend HETLIOZ Coverage to Patients With Non-24 Who Are Not Totally Blind

A patient filed a federal lawsuit challenging the unlawfulness of Colorado Medicaid's prior authorization criteria for HETLIOZ coverage.

  • The Lancet: Hetlioz, Taken Daily at Fixed Time, Promotes Master Body Clock Entrainment

  • What You Need to Know About Non-24

  • In Europe, Hetlioz Receives Positive CHMP Opinion

  • National Organization for Rare Disorders to Honor Hetlioz

  • In Q42014, Hetlioz Sales Increase 15% Compared to Q32014

  • Hetlioz US Sales Grow to $5.2 Million in First Full Quarter Since Launch

Non-24-Hour Disorder

Latest

More Than 420 Prescriptions Written for Hetlioz

“We are encouraged by the early positive reception of Hetlioz by patients, physicians, and payors. We look forward to more patients benefiting from Hetlioz in the coming months and years,” says Mihael Polymeropoulos...

  • European Medicines Agency Accepts Hetlioz Marketing Authorization Application

    European Medicines Agency Accepts Hetlioz Marketing Authorization Application

  • Vanda Reports Net Loss of $26.5 Million Due in Part to Hetlioz Launch Expenses

    Vanda Reports Net Loss of $26.5 Million Due in Part to Hetlioz Launch Expenses

  • Blind Adventurer Raises Awareness of Non-24 with Vanda Pharmaceuticals

    Blind Adventurer Raises Awareness of Non-24 with Vanda Pharmaceuticals

  • FDA Approves Hetlioz for Non-24-Hour Disorder

    FDA Approves Hetlioz for Non-24-Hour Disorder

  • Tasimelteon Resets Body Clock in Non-24-Hour Sleep-Wake Disorder

    Tasimelteon Resets Body Clock in Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Disorder

Latest
Sorry, No Posts Found
Sorry, No Posts Found

Sleep Review

7300 W 110th St – Floor 7
Overland Park, KS 66210

Our Parent Company

MEDQOR LLC

About MEDQOR

MEDQOR Data Platform

Media Solutions Kit

Press Releases

Key Resources

Digital Edition

Podcasts

Webinars

White Papers

Videos

Helpful Links

Submit a Press Release

Advisory Board

Submit an Article

Subscribe

Contact Us

  • Follow
  • Follow
  • Follow
  • Follow

Copyright

Privacy Policy

Terms of Service

© 2026 MEDQOR LLC. All Rights Reserved

✖